Ionis Pharmaceuticals Inc. (IONS)
NASDAQ:IONS
Want to see IONS full AI Analyst Report?
IONS Stock Chart & Stats
$75.26
-$0.75(-2.14%)
At close: 4:00 PM EST
$75.26
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$27.90 - $86.74
Previous CloseN/A
Volume126.35K
Average Volume (3M)2.03M
Market Cap
$12.69B
Enterprise Value$14.75B
Total Cash (Recent Filing)$2.68B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Apr 29, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding165,192,020
10 Day Avg. Volume1,293,465
30 Day Avg. Volume2,033,116
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue15.63
Enterprise Value/Gross Profit15.90
Enterprise Value/Ebitda3.25
Forecast
1Y Price Target
$100.25Price Target Upside33.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$825.50M
Bulls Say, Bears Say
Bulls Say
Clinical Outcomes And Payer ValuePhase 3 data showing a statistically significant reduction in acute pancreatitis establishes a clear clinical benefit that supports reimbursement and prescriber adoption.
Partner Licensing And Commercial De-riskingA licensing agreement that assigns ex-U.S. commercialization to a regional partner delivers upfront and milestone payments plus royalties while the partner funds regulatory filings and launches, lowering commercialization costs and providing near-term non-dilutive cash.
Regulatory Approval And Market ExpansionEuropean regulatory validation for an indication extension in severe hypertriglyceridemia enables commercialization outside the U.S., expands the treatable patient population and reduces execution risk in a major market.
Bears Say
Deal Economics UncertaintyUndisclosed timing and size of upfront, milestone and royalty payments create uncertainty about the exact ex-U.S. economics and the company's future revenue stream.
Leverage And Balance Sheet RiskElevated net debt relative to equity increases financial leverage and could constrain strategic flexibility and investor valuation.
Payer Access And Pricing PressureFailure of payer access assumptions or tougher payor negotiations could force increased discounts and lower net prices, limiting coverage and reducing peak sales potential.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?
Ionis Pharmaceuticals Inc. lowest stock price was $27.90 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals Inc.’s market cap?
Ionis Pharmaceuticals Inc.’s market cap is $12.69B.
When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?
Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Apr 29, 2026 which is in 11 days.
How were Ionis Pharmaceuticals Inc.’s earnings last quarter?
Ionis Pharmaceuticals Inc. released its earnings results on Feb 25, 2026. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$1.319 by -$0.091.
Is Ionis Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued.
Does Ionis Pharmaceuticals Inc. pay dividends?
Ionis Pharmaceuticals Inc. does not currently pay dividends.
What is Ionis Pharmaceuticals Inc.’s EPS estimate?
Ionis Pharmaceuticals Inc.’s EPS estimate is -0.88.
How many shares outstanding does Ionis Pharmaceuticals Inc. have?
Ionis Pharmaceuticals Inc. has 165,192,020 shares outstanding.
What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?
Ionis Pharmaceuticals Inc. reported an EPS of -$1.41 in its last earnings report, missing expectations of -$1.319. Following the earnings report the stock price went down -5.29%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.25 (33.20% Upside)
$100.25 (33.20% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 745.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.46%
12-Months-Change
Fundamentals
Return on Equity
-68.82%
Trailing 12-Months
Asset Growth
17.32%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: multiple successful launches (TRYNGOLZA, DAWNZERA), landmark Phase III data (olezarsen, zilganersen), 34% revenue growth in 2025, expanding commercial infrastructure and robust partner progress underpin confident guidance and multibillion-dollar peak potential for key programs. Notable near-term risks and conservatism tempering outlook include guidance assuming a standard sNDA review (delaying broader sHTG sales), expected TRYNGOLZA revenue decline during transition and pricing negotiations, projected non-GAAP operating losses as commercial investments continue, cash use for debt repayment, and binary clinical/regulatory readouts (e.g., HORIZON) that carry execution risk. Overall, positive operational and clinical achievements substantially outweigh these manageable near-term financial and timing risks.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$100.25
▲(33.20% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---